Literature DB >> 18523057

Stroke is a coronary heart disease risk equivalent: implications for future clinical trials in secondary stroke prevention.

Pierre Amarenco1, Philippe Gabriel Steg.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18523057     DOI： 10.1093/eurheartj/ehn232

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  9 in total

1.  Adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes.

Authors:  Sylvie Perreault; Amy Y X Yu; Robert Côté; Alice Dragomir; Brian White-Guay; Stéphanie Dumas
Journal:  Neurology       Date:  2012-10-31       Impact factor: 9.910

2.  Spontaneous coronary thrombosis following thrombolytic therapy for acute cardiovascular accident and stroke: a case study.

Authors:  Eric L Wallace; Susan S Smyth
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

3.  Interactions between cardiovascular and cerebrovascular disease.

Authors:  Giuseppe Di Pasquale; Stefano Urbinati; Enrica Perugini; Simona Gambetti
Journal:  Curr Treat Options Neurol       Date:  2012-12       Impact factor: 3.598

4.  Atorvastatin in stroke: a review of SPARCL and subgroup analysis.

Authors:  Branko N Huisa; Andrew B Stemer; Justin A Zivin
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

5.  Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update.

Authors:  Hermann Toplak; Bernhard Ludvik; Monika Lechleitner; Hans Dieplinger; Bernhard Föger; Bernhard Paulweber; Thomas Weber; Bruno Watschinger; Sabine Horn; Thomas C Wascher; Heinz Drexel; Marianne Brodmann; Ernst Pilger; Alexander Rosenkranz; Erich Pohanka; Rainer Oberbauer; Otto Traindl; Franz Xaver Roithinger; Bernhard Metzler; Hans-Peter Haring; Stefan Kiechl
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

6.  SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.

Authors:  Sanghyun Ahn; Joongyub Lee; Seung-Kee Min; Jongwon Ha; Sang-Il Min; Song-Yi Kim; Min-Ji Cho; Sungsin Cho
Journal:  Trials       Date:  2017-09-22       Impact factor: 2.279

7.  New Imaging Signatures of Cardiac Alterations in Ischaemic Heart Disease and Cerebrovascular Disease Using CMR Radiomics.

Authors:  Elisa Rauseo; Cristian Izquierdo Morcillo; Zahra Raisi-Estabragh; Polyxeni Gkontra; Nay Aung; Karim Lekadir; Steffen E Petersen
Journal:  Front Cardiovasc Med       Date:  2021-09-23

8.  Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials.

Authors:  Qiao Yu Shao; Zhi Jian Wang; Xiao Teng Ma; Xu Ze Lin; Liu Pan; Yu Jie Zhou
Journal:  BMC Cardiovasc Disord       Date:  2021-12-01       Impact factor: 2.298

9.  Metabolic syndrome in patients with first-ever ischemic stroke: prevalence and association with coronary heart disease.

Authors:  Yajun Liang; Zhongrui Yan; Yanlei Hao; Qiqi Wang; Zuoji Zhang; Rui She; Peng Wang; Yifeng Du; Joseph Tf Lau; Joost Dekker; Bo Bai; Chengxuan Qiu
Journal:  Sci Rep       Date:  2022-07-29       Impact factor: 4.996
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.